Company / Accounts Receivable
Gilead Sciences Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$4.9B
FY2025
5-year range
$4.4B / $4.9B
FY2021-FY2025
Trend
+11.2%
vs FY2024
Sector context
#9 of 113
Health Care
What the data says
Among 113 Health Care companies, Gilead Sciences is in the top 8% for accounts receivable. Accounts Receivable returned to growth in FY2025 after 2 years of decline, reaching $4.9B.
Based on SEC 10-K filings.
$4.9B in FY2025 with a 5-year CAGR of +0.1%. Top quartile in the Health Care sector.
Improved from $4.7B to $4.9B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +0.9%
- 5-Year CAGR
- +0.1%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 113This company $4.9B Sector average $1.1B
▼
+331.9% above sector average
Key checks
Key Insights
- 5-year CAGR of +0.1%, indicating consistent growth.
- In FY2025, accounts receivable increased 11.2% year-over-year.
- Ranks #9 out of 113 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2018.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.9B | +11.2% |
| FY2024 | $4.4B | -5.2% |
| FY2023 | $4.7B | -2.4% |
| FY2022 | $4.8B | +6.3% |
| FY2021 | $4.5B | -8.2% |
| FY2020 | $4.9B | +36.6% |
| FY2019 | $3.6B | +7.7% |
| FY2018 | $3.3B | -13.6% |
| FY2017 | $3.9B | -14.7% |
| FY2016 | $4.5B | -22.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026